
Search
Filter Results
Displaying 1–10 of 33 news results
-
Jun 15, 2022
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
May 12, 2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
-
Mar 3, 2022
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
Industry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
Jan 6, 2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Investment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
Jan 5, 2022
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
-
Jan 5, 2022
Dr. Thomas Chalberg has been recognized by the Foundation Fighting Blindness for his pioneering contributions to research and development.
-
Dec 22, 2021
Organizations collaborate on inherited macular dystrophy program
The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon Visions Foundation Inherited Macular Dystrophy Program, according to a news release from the organizations.
-
Dec 14, 2021
Eyes On Eyecare Raises $1,500 for Foundation Fighting Blindness
Over 1,400 people participated in charitable giving initiative.
-
Dec 9, 2021
Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
-
Oct 20, 2021
Opus Genetics Announces Two Key Leadership Appointments
Dr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.